Stay in touch about special discounts, nutrition tips and additional education.
Our clinical trial.
We conducted a double-blind, placebo-controlled nutrition study that demonstrated:
- Pendulum Glucose Control’s safety
- Pendulum Glucose Control statistically and clinically significant impact on A1C and post-meal blood-glucose spikes
Clinical trial included participants taking metformin, compared to placebo. 1. Regarding the decreased A1C level, there was a reduction in mean A1C compared to placebo. 2. Regarding the Post Prandial Glucose Spike Reduction, the observed reduction in glucose AUC would be expected to increase the time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring. Increases in TIR70-180 strongly correlate to both reductions in AC1C and reduction in risk for complications in T2D patients (see details here).
The link between metabolism and microbiome.
Research has shown that Type 2 diabetes is linked to an imbalance in the gut microbiome. Specifically, people with diabetes are shown to have low levels of Akkermansia muciniphila and other probiotic strains that help digest dietary fiber to produce butyrate, a crucial short-chain fatty acid needed for balancing glucose and supporting the gut lining.
The science behind Pendulum’s main product, Pendulum Glucose Control, has demonstrated that it helps lower A1C and manage blood sugar spikes in people with Type 2 diabetes taking metformin.
Butyrate: A powerful byproduct in a balanced microbiome.
Butyrate is critically important for digestive and metabolic health. It feeds the cells in our gut and creates a favorable environment for other good bacteria to grow. More than 5,000 research studies have shown that butyrate plays several important roles in the body:
- 1 Major fuel source for cells lining the large intestine.
- 2 Helping maintain the gut lining.
- 3 Helps improve immunity by defending against permeability.
- 4 Stimulates GLP-1, a hormone produced by the gut, which helps maintain a healthy balance between insulin and glucose levels.
- 5 Helps manage certain symptoms of Type 2 diabetes.
But, our bodies don’t produce any butyrate on their own.
Our strains deserve a spotlight
Akkermansia muciniphila
Clostridium butyricum
Clostridium beijerinckii
Anaerobutyricum hallii
Bifidobacterium infantis
Chicory inulin
No one could manufacture these novel strains—so we built our own facility.
The Pendulum manufacturing facility is as unique as the probiotic strains grown within it. Why? Our strains are the heavy-hitters, the ones that live and thrive where there’s absolutely no oxygen - in your colon - and they can only exist in a comparable environment.
Anaerobic probiotics require a completely oxygen-free environment.
In order to grow Akkermansia and our other strict anaerobes, we had to create our own closed-system facility to ensure the complete absence of oxygen from start to finish.
Fun Facts
We’re honored to serve alongside our prestigious board members.
Board of Directors
Adam D’augelli
Partner
True Ventures
Colleen Cutcliffe
CEO
pendulum therapeutics
Craig Sherman, General Partner
Meritech Capital
Heather Mason
Fmr. SVP
Abbott Nutrition
Fmr. SVP
Abbott Diagnostics
Hugh Martin
CEO
Lacuna Technologies
Sensity Biosystems (acq Verizon)
Pacific Biosciences (IPO)
ONI Systems (IPO)
John Eid
CSO
pendulum therapeutics
Peter Barton Hutt, Senior Counsel
Senior Counsel
Covington & Burling
Fmr. General Counsel
FDA
Roelof Botha
Seed & Early, Growth Partner
Sequoia Capital
Medical Advisory Board
Anne Peters, MD
Director, Clinical Diabetes
University of Southern California Private Practice
Carol Wysham, MD
Professor
University of Washington
Practitioner
Rockwood Multicare Center for Diabetes
Davida Krueger, NP
Nurse Practitioner
Henry Ford Health System
Chair
American Diabetes Association (ADA) Research Foundation
Emeran Mayer, MD
Director, Oppenheimer Center For Neurobiology of Stress and Resilience
Professor, Department of Medicine
UCLA
Jay Pasricha, MD
Chief of Medicine
Mayo Clinic
John Buse, MD
Chair, Division of Endocrinology
University of North Carolina School of Medicine
Purna Kashyap, MBBS
Associate Professor, Medicine
Mayo Clinic
Robert Ratner, MD
Chief Medical Officer
Virta Health
Fmr Chief Scientific & Medical Officer
American Diabetes Association
Scientific Advisory Board
Alfred Spormann, Ph.D.
PROFESSOR, CIVIL AND ENVIRONMENTAL ENGINEERING
STANFORD UNIVERSITY
Christopher Mason, Ph.D.
Professor
WEILL Cornell medicine
Director of Emerging Genome Technologies
Tempus Labs, Inc.
Dietrich Stephan, Ph.D.
CEO
NEUBASE THERAPEUTICS
CHAIR, DEPARTMENT OF HUMAN GENETICS
UNIVERSITY OF PITTSBURGH
Eric Schadt, Ph.D.
FOUNDER & CEO
SEMA4
DEAN FOR PRECISION MEDICINE
Icahn School of Medicine at Mount Sinai
Peter Turnbaugh, Ph.D.
ASSISTANT PROFESSOR, DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY
UCSF